Entrada Therapeutics revenue was $210.78M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $37.4M, up 91.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TRDA annual revenue was $210.8M, with 63.4% growth year-over-year.
TRDA past revenue growth
How has TRDA's revenue growth performed historically?
Entrada Therapeutics (NASDAQ: TRDA) reported Q4 2024 revenue of $37.40 million up 10.63% year over year. In the same quarter last year, Entrada Therapeutics's revenue was $41.85 million.
What was Entrada Therapeutics's revenue in 2024?
Entrada Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $210.78 million, a 63.38% increase year over year.
How much does Entrada Therapeutics make in a day?
Based on Entrada Therapeutics annual revenue for the past five years, TRDA makes an average of $186,189.04 per day.
What was Entrada Therapeutics's annual revenue growth in the past year?
As of Q1 2025, Entrada Therapeutics's revenue has grown 63.38% year over year. This is 358.05 percentage points lower than the US Biotechnology industry revenue growth rate of 421.43%. Entrada Therapeutics's revenue in the past year totaled $210.78 million.
How much does Entrada Therapeutics make in a year?
Entrada Therapeutics's revenue by year for the past five years is:
Entrada Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $210.78 million, a 63.38% increase year over year.
Entrada Therapeutics's annual revenue for Dec 31, 2023 was $129.01 million, a Infinity% increase from 2022.
Entrada Therapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Entrada Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Entrada Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.